Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus oxycodone/naloxone PR in non-opioid pre-treated subjects with uncontrolled severe chronic low back pain with a neuropathic pain component.

Trial Profile

Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus oxycodone/naloxone PR in non-opioid pre-treated subjects with uncontrolled severe chronic low back pain with a neuropathic pain component.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs Tapentadol (Primary) ; Oxycodone/naloxone
  • Indications Back pain; Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Grunenthal
  • Most Recent Events

    • 04 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Apr 2013 Planned end date changed from 25 Apr 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 24 Apr 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01838616).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top